Wolwo Pharma(SZ:300357) Xin Lang Cai Jing·2025-09-24 03:17Core Viewpoint - Iwubio has shown a significant stock price increase of 42.54% year-to-date, despite recent declines in the short term [1][2]. Financial Performance - For the first half of 2025, Iwubio reported revenue of 484 million yuan, representing a year-on-year growth of 12.81% [2]. - The net profit attributable to shareholders for the same period was 177 million yuan, reflecting an 18.61% increase compared to the previous year [2]. Stock Market Activity - As of September 24, Iwubio's stock price was 28.65 yuan per share, with a market capitalization of 15 billion yuan [1]. - The stock experienced a trading volume of 114 million yuan and a turnover rate of 0.83% on the same day [1]. - The stock has seen a decline of 4.72% over the last five trading days and 7.43% over the last twenty days [1]. Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 3.53% to 34,600 [2]. - The average number of circulating shares per shareholder increased by 3.66% to 13,999 shares [2]. Dividend Distribution - Since its A-share listing, Iwubio has distributed a total of 913 million yuan in dividends, with 317 million yuan distributed over the last three years [3]. Major Shareholders - As of June 30, 2025, the fifth largest circulating shareholder is the China National Bio-Medical Index A, holding 4.69 million shares, a decrease of 188,000 shares from the previous period [3]. - The seventh largest shareholder is the Hong Kong Central Clearing Limited, holding 4.11 million shares, down by 491,800 shares [3].